Press release: late-breaking phase 3 data at aad 2022 show dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Late-breaking p hase 3 data at aad 2022 show dupixent ® (dupilumab) significantly improved signs and symptoms of prurigo n odularis

REGN Ratings Summary

REGN Quant Ranking